Sugi Predict

Sugi Predict / Compounds / SCHEMBL6712094

SCHEMBL6712094

SCHEMBL6712094

CC(C)c1cnc(N(C(N)=O)c2ccc3cn[nH]c3c2)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.38
▸ SYK P43405 2/20 0.37
▸ INSR P06213 1/20 0.37
▸ IGF1R P08069 1/20 0.37
▸ MAPT P10636 5/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ F2 P00734 1/20 0.35
▸ NEK2 P51955 1/20 0.35
▸ AR P10275 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ PER2 O15055 1/20 0.35
▸ CRY1 Q16526 1/20 0.35
▸ CRY2 Q49AN0 1/20 0.35
▸ CCNE1 P24864 1/20 0.34
▸ CDK2 P24941 1/20 0.34
▸ CDK5 Q00535 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6712093 0.85 MAOA (0.35) ALDH1A1SYKKDM4ECCNE1CDK2
SCHEMBL6712223 0.80 SYK (0.37) SYKF2ARPER2CRY1
SCHEMBL6710801 0.79 KDM4E (0.36) KDM4EMEN1KMT2ACCNE1CDK2
SCHEMBL6715903 0.78 TRPA1 (0.35) ALDH1A1MEN1KMT2ACCNE1CDK2
SCHEMBL6709655 0.78 ALOX5 (0.33) MEN1KMT2AHTTCCNE1CDK2
SCHEMBL6709584 0.78 ALDH1A1 (0.44) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL7257113 0.78 CDK2 (0.38) ALDH1A1CCNE1CDK2CDK5LMNA
SCHEMBL27570619 0.78 CDK2 (0.38) ALDH1A1CCNE1CDK2CDK5
SCHEMBL27572548 0.78 CDK2 (0.38) ALDH1A1CCNE1CDK2CDK5LMNA
SCHEMBL6761024 0.77 CDK2 (0.34) ALDH1A1CCNE1CDK2CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1325390-A 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2001-12-05 — — CN claimed
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 — — US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 — — US disclosed
CN-1325390-A 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2001-12-05 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 ALDH1A1 903/4885SYK 1366/4885INSR 514/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 ALDH1A1 903/4885SYK 1366/4885INSR 514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.